# Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

> **NCT01298076** · PHASE2 · COMPLETED · sponsor: **University of Sydney** · enrollment: 61 (actual)

## Conditions studied

- Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01298076
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298076, "Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01298076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*